MedTrace Logo

Study of EOC317 in Chinese Patients With Advanced Solid Tumors

NCT03583125 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2019-09-11

No results posted yet for this study

Summary

This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

EOC317

tablet(s) PO

Sponsors & Collaborators

  • Taizhou EOC Pharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hongming Pan, M.D. · Sir Run Run Shaw Hospital, Zhejiang, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-29
Primary Completion
2020-02-29
Completion
2020-11-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03583125 on ClinicalTrials.gov